CFO updates stated that Roivant ended the quarter with $5.2 billion in cash and marketable securities, including $500 million authorized for additional share buybacks and $1 billion in stock ...

In 2024, the Food and Drug Administration (FDA) approved Vyvgart Hytrulo, a new effective treatment for CIDP in adults. Vyvgart Hytrulo works by reducing the level of pathogenic (disease-causing ...

Albert Fiori was diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy or CIDP, a rare autoimmune disease that affects his eye, one arm and one leg. But he is not letting that stop him from ...

Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026. Neurology Program: ...

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to ...

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with biotechnology startup FcR Therapeutics to develop recombinant nanobodies ...

Roivant Sciences Ltd (ROIV) showcases strong financials and strategic advancements while navigating ongoing litigation and competitive pressures.

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, ...